Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Revenue $ 362,500 $ 250,000 $ 1,112,500
Operating costs and expenses:        
Inventor royalties, contingent legal fees, litigation and licensing expenses related to patent assertion 241,157 166,250 767,180
Amortization of patents 41,875 81,324 418,750 243,972
Research and development expenses (including non-cash share-based compensation expenses of $338,449 and $2,472,489, $2,567,294 and $2,668,315, respectively) 1,085,574 2,942,071 4,602,239 4,380,137
General and administrative expenses (including non-cash share-based compensation expenses of $492,449 and $2,155,844 $2,335,218 and $2,558,701, respectively) 1,056,963 2,703,752 4,405,385 4,602,555
Impairment in carrying amount of patent asset (Note 1) 418,750
Total operating costs and expenses 2,184,412 5,968,304 10,011,374 9,993,844
Loss from operations (2,184,412) (5,605,804) (9,761,374) (8,881,344)
Interest income 18,364 12,228 53,783 29,780
Loss before income taxes (2,166,048) (5,593,576) (9,707,591) (8,851,564)
Provision for income taxes
Net loss (2,166,048) (5,593,576) (9,707,591) (8,851,564)
Less: Net loss attributable to noncontrolling interest (26,020) (116,650) (148,030) (158,032)
Net loss attributable to common shareholders $ (2,140,028) $ (5,476,926) $ (9,559,561) $ (8,693,532)
Net loss per common share attributable to common shareholders:        
Basic and diluted (in Dollars per share) $ (0.11) $ (0.30) $ (0.49) $ (0.50)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 20,100,915 18,431,025 19,638,833 17,257,546